10. Commitments and Contingencies Employment Agreements The Company has entered into employment agreements with its president and chief executive officer, chief financial officer, chief business officer, chief medical officer, chief commercial officer and senior vice president of research and development, that provide for, among other things, salary, bonus and severance payments. Legal Proceedings As a result of the Company s acquisition of SPRIX from Luitpold and in-license of OXAYDO from Acura in January 2015, the Company has been substituted or otherwise become subject to certain legal proceedings involving SPRIX and OXAYDO, which are further described below. On August 10, 2012, Luitpold, the prior exclusive licensee of U.S. Patent No. 6,333,044 (the   044 patent ), filed a complaint in federal district court in New Jersey for infringement of the  044 patent against Amneal Pharmaceuticals, LLC et al. in response to Amneal s submission of ANDA No. 23-382 to the FDA for a generic version of SPRIX. Luitpold sought an injunction to prevent Amneal s launch of a generic version of SPRIX. On November 19, 2013, Luitpold and Amneal entered into a settlement and license agreement permitting Amneal to launch its generic product on or after March 25, 2018 subject to royalty payments. On January 26, 2015, the Company was substituted for Luitpold as plaintiff in a patent litigation in federal district court in New Jersey against Apotex Corp. and Apotex, Inc. (collectively,  Apotex ), involving the SPRIX Nasal Spray. Apotex submitted ANDA No. 20-5486 to the FDA seeking approval for a generic version of SPRIX. On July 11, 2014, Luitpold had filed a complaint for infringement of the  044 patent against Apotex, prompting a 30-month stay on the approval of Apotex s ANDA by the FDA. This litigation is currently ongoing. The Company is aggressively defending its legal position to preserve the exclusivity of SPRIX in the market. As is the case with patent litigation, there is a risk that the  044 patent may be invalidated, unenforc